1,382 results on '"Bria, Emilio"'
Search Results
2. Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients
3. Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC)
4. Integrating nutrition, physical exercise, psychosocial support and antiemetic drugs into CINV management: The road to success
5. Gender minorities in breast cancer – Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients
6. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
7. Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer
8. Correction: Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study
9. Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study
10. Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
11. Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study)
12. Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program
13. Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation
14. Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies
15. Maintenance strategies after anti-EGFR-based induction in metastatic colorectal cancer: A systematic review and bayesian network meta-analysis
16. Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results
17. RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion
18. Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors
19. The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis
20. Predictive and prognostic effect of computed tomography–derived body composition analysis during neoadjuvant chemotherapy for operable and locally advanced breast cancer
21. Loss of FGFR4 promotes the malignant phenotype of PDAC
22. Simultaneous Integrated Boost (Sib) Intensity-Modulated Radiotherapy for Treatment of Bone Metastases: Analysis of a Breast Cancer Cohort
23. Implementation of Artificial Intelligence in Personalized Prognostic Assessment of Lung Cancer: A Narrative Review
24. Role of Peripheral Blood Markers for Detecting Response and Predicting Prognosis in Patients with Non-small-cell Lung Cancer Undergoing Neoadjuvant Therapy and Surgery
25. Effect of exercise on functional capacity in patients with advanced cancer: A meta-analysis of randomized controlled trials
26. Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer
27. Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study
28. High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status
29. Intracranial outcomes of 1L selpercatinib in advanced RET fusion-positive NSCLC: LIBRETTO-431 study.
30. Outcomes of Radiotherapy in Oligoprogressive Breast Cancer.
31. Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK‐positive advanced non–small cell lung cancer.
32. CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non–Small Cell Lung Cancer.
33. Intrathoracic Lymph Node Microcalcifications are Associated With a High Prevalence of Malignancy and Anaplastic Lymphoma Kinase Rearrangement: The "Calce" Study.
34. The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis.
35. Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK‐positive advanced nonsmall cell lung cancer
36. Accessible Machine Learning and Deep Learning Models Predict Response and Survival in Early Stage Hormone Receptor-Positive/HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
37. Response to first-line pembrolizumab in metastatic KRAS-mutated non-small-cell lung cancer
38. Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial
39. PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non–small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors
40. Nutritional Support in Lung Cancer Patients: The State of the Art
41. Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis
42. Sequential chemo-hypofractionated RT versus concurrent standard CRT for locally advanced NSCLC: GRADE recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO)
43. Correction: Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation
44. Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study
45. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes
46. Collagenous colitis and atezolizumab therapy: an atypical case
47. Mediastinal Up-Staging During Surgery in Non–Small-Cell Lung Cancer: Which Mediastinal Lymph Node Metastasis Patterns Better Predict The Outcome? A Multicenter Analysis
48. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
49. Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model
50. Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.